HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA)
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary HOPE Therapeutics has received final clearance from Florida's Agency for Health Care Administration (AHCA) to proceed with the acquisition of Dura Medical. Dura Medical, founded in 2018, is a revenue-generating and EBITDA-positive healthcare provider specializing in precision psychiatry services on Florida's west coast.
The acquisition, along with previously announced purchases of Neurospa TMS and Cohen and Associates, will expand HOPE's presence in Florida. Dura Medical provides advanced treatments including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), and Spravato® for depression, PTSD, and related disorders. The company aims to treat over 10,000 patients by 2026 and serves both civilian and veteran patients through the Veterans Affairs Community Cares Network.
NRx Pharmaceuticals (NASDAQ:NRXP) ha annunciato che la sua controllata HOPE Therapeutics ha ottenuto l'approvazione definitiva dall'Agenzia per l'Amministrazione Sanitaria della Florida (AHCA) per procedere con l'acquisizione di Dura Medical. Fondata nel 2018, Dura Medical è un fornitore di servizi sanitari con ricavi e EBITDA positivi, specializzato in servizi di psichiatria di precisione sulla costa occidentale della Florida.
Questa acquisizione, insieme agli acquisti precedentemente annunciati di Neurospa TMS e Cohen and Associates, amplierà la presenza di HOPE in Florida. Dura Medical offre trattamenti avanzati tra cui terapia di infusione di ketamina, stimolazione magnetica transcranica (TMS) e Spravato® per depressione, PTSD e disturbi correlati. L'azienda punta a trattare oltre 10.000 pazienti entro il 2026 e serve sia pazienti civili che veterani attraverso il Veterans Affairs Community Cares Network.
NRx Pharmaceuticals (NASDAQ:NRXP) anunció que su subsidiaria HOPE Therapeutics ha recibido la aprobación final de la Agencia de Administración de Atención Médica de Florida (AHCA) para proceder con la adquisición de Dura Medical. Fundada en 2018, Dura Medical es un proveedor de servicios de salud con ingresos y EBITDA positivos, especializado en servicios de psiquiatría de precisión en la costa oeste de Florida.
La adquisición, junto con las compras previamente anunciadas de Neurospa TMS y Cohen and Associates, ampliará la presencia de HOPE en Florida. Dura Medical ofrece tratamientos avanzados que incluyen terapia de infusión de ketamina, estimulación magnética transcraneal (TMS) y Spravato® para la depresión, TEPT y trastornos relacionados. La compañía tiene como objetivo tratar a más de 10,000 pacientes para 2026 y atiende tanto a pacientes civiles como veteranos a través de la Veterans Affairs Community Cares Network.
NRx Pharmaceuticals (NASDAQ:NRXP)는 자회사 HOPE Therapeutics가 플로리다 보건관리국(AHCA)으로부터 Dura Medical 인수에 대한 최종 승인을 받았다고 발표했습니다. 2018년에 설립된 Dura Medical은 플로리다 서해안에서 정밀 정신의학 서비스를 제공하는 수익 창출 및 EBITDA 긍정적인 의료 서비스 제공업체입니다.
이번 인수는 이전에 발표된 Neurospa TMS 및 Cohen and Associates 인수와 함께 HOPE의 플로리다 내 입지를 확대할 것입니다. Dura Medical은 우울증, PTSD 및 관련 장애에 대해 케타민 주입 치료, 경두개 자기 자극(TMS), Spravato® 등 첨단 치료를 제공합니다. 회사는 2026년까지 10,000명 이상의 환자를 치료하는 것을 목표로 하며, 재향군인 커뮤니티 케어 네트워크를 통해 민간인과 재향군인 모두를 대상으로 서비스를 제공합니다.
NRx Pharmaceuticals (NASDAQ:NRXP) a annoncé que sa filiale HOPE Therapeutics a reçu l'autorisation finale de l'Agence de gestion des soins de santé de Floride (AHCA) pour procéder à l'acquisition de Dura Medical. Fondée en 2018, Dura Medical est un prestataire de soins de santé générant des revenus et un EBITDA positif, spécialisé dans les services de psychiatrie de précision sur la côte ouest de la Floride.
Cette acquisition, ainsi que les achats précédemment annoncés de Neurospa TMS et Cohen and Associates, permettront d'étendre la présence de HOPE en Floride. Dura Medical propose des traitements avancés incluant la thérapie par perfusion de kétamine, la stimulation magnétique transcrânienne (TMS) et Spravato® pour la dépression, le trouble de stress post-traumatique (TSPT) et les troubles associés. L'entreprise vise à traiter plus de 10 000 patients d'ici 2026 et dessert à la fois des patients civils et des vétérans via le Veterans Affairs Community Cares Network.
NRx Pharmaceuticals (NASDAQ:NRXP) gab bekannt, dass seine Tochtergesellschaft HOPE Therapeutics die endgültige Genehmigung der Florida Agency for Health Care Administration (AHCA) erhalten hat, um mit der Übernahme von Dura Medical fortzufahren. Dura Medical, gegründet im Jahr 2018, ist ein umsatzstarkes und EBITDA-positives Gesundheitsunternehmen, das sich auf Präzisionspsychiatrie an der Westküste Floridas spezialisiert hat.
Die Übernahme, zusammen mit den zuvor angekündigten Käufen von Neurospa TMS und Cohen and Associates, wird die Präsenz von HOPE in Florida erweitern. Dura Medical bietet fortschrittliche Behandlungen an, darunter Ketamininfusionstherapie, transkranielle Magnetstimulation (TMS) und Spravato® für Depressionen, PTBS und verwandte Störungen. Das Unternehmen plant, bis 2026 über 10.000 Patienten zu behandeln und versorgt sowohl zivile als auch Veteranenpatienten über das Veterans Affairs Community Cares Network.
- None.
- Acquisition still subject to standard closing conditions
- Integration of multiple acquisitions (Neurospa TMS, Cohen and Associates) may present operational challenges
Insights
NRXP cleared to close Dura Medical acquisition, expanding mental health services in Florida with revenue-positive business that treats depression and PTSD.
The final regulatory approval from Florida's Agency for Health Care Administration marks a significant milestone for NRx Pharmaceuticals' expansion strategy. Dura Medical represents a strategically valuable asset as it's both revenue-generating and EBITDA positive, meaning this acquisition should immediately strengthen NRx's financial position rather than being a cash drain.
Dura's specialized mental health services - including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation, Spravato®, and Stellate Ganglion Blocks - position NRx to capitalize on the growing interventional psychiatry market. The acquisition complements NRx's previously announced acquisitions of Neurospa TMS and Cohen and Associates, creating a comprehensive mental health network along Florida's West Coast.
Particularly noteworthy is Dura's existing contract with the Veterans Affairs Community Cares Network, providing a stable revenue stream through government reimbursement while serving the underserved veteran population suffering from treatment-resistant depression and PTSD. This government relationship could potentially be leveraged to accelerate insurance coverage for NRx's treatments.
This acquisition represents more than geographic expansion - it brings in leadership with specialized expertise in combining psychedelic medications with neuroplastic technologies, potentially accelerating NRx's clinical innovation. The founder's ambitious goal to treat 10,000 people by 2026 suggests confidence in substantial growth potential for these services.
Florida's Agency for Health Care Administration (AHCA) approval is a critical regulatory step toward closing the Dura Medical acquisition- Dura Medical, together with previously-announced acquisitions of Neurospa TMS, and Cohen and Associates, to provide coverage along the West Coast of
Florida - Dura delivers a full range of precision psychiatry services for severe depression, PTSD and related CNS disorders, including Ketamine therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients
- Acquisition expected to be accretive to revenue and EBITDA
Dura Medical was founded in 2018 to offer a gold-standard, precision approach to treating mental health and chronic pain on the west coast of Florida. The clinics leverage the latest interventional psychiatry procedures, including Ketamine Infusion Therapy, Transcranial Magnetic Stimulation (TMS), Spravato® and Stellate Ganglion Blocks, augmented by traditional psychiatry and therapy to provide a full continuum of care for people with depression, suicidality, PTSD, anxiety, and related disorders.
A former nurse anesthetist in the US Army Reserve, Mr. Durand and Dura Medical are proud to provide for the Veterans Affairs Community Cares Network (VA CCN) under an agreement with the US Department of Veterans Affairs to ensure that military veterans have full access to Ketamine Infusion Therapy, TMS and Spravato®, in addition to Traumatic Incident Reduction Therapy (TIR).
"We founded Dura Medical with the mission to reduce suicide in our community and aim to treat more than 10,000 people by 2026. We're excited to align mission with the HOPE Network and to lead HOPE's expansion in
"We are pleased to receive this clearance from AHCA and will move expeditiously toward closing this landmark acquisition for HOPE." said Jonathan Javitt, MD MPH and Matthew Duffy, Co-CEOs of HOPE Therapeutics. "Further, Mr. Durand has been a pioneer in combining the use of psychedelic medications with neuroplastic technologies, including TMS in the treatment of suicidal depression and PTSD. We are excited to incorporate Stephen and Liz Durand's tradition of excellence and commitment to patient care for civilians and veterans alike into HOPE's
The intended closing of the of Dura acquisition is subject to satisfaction of standard closing conditions.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy, for suicidal treatment-resistant bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia.
NRx recently filed for a new Commissioner's National Priority Voucher (CNPV) for NRX-100 (preservative free IV ketamine); the CNPV is designed to facilitate approval of drugs to enhance the health interests of Americans. Additionally, NRx recently filed an Abbreviated New Drug Application (ANDA) for NRX-100 for use in ketamine's currently approved indications. Further, the Company has initiated a New Drug Application filing for NRX-100 for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality and has filed a patent for this novel formulation with the US Patent and Trademark Office.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information: | |
Matthew Duffy | Brian Korb |
Co-CEO, Hope Therapeutics, Inc. | Managing Partner, astr partners |
Chief Business Officer, NRx Pharmaceuticals, Inc. | (917) 653-5122 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-announce-receipt-of-final-clearance-to-proceed-to-closing-of-dura-medical-acquisition-from-floridas-agency-for-health-care-administration-ahca-302525049.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What regulatory approval did NRXP receive for the Dura Medical acquisition?
What services does Dura Medical provide under NRXP?
How many patients does Dura Medical aim to treat under NRXP by 2026?
Is the Dura Medical acquisition expected to be profitable for NRXP?
How does the Dura Medical acquisition fit into NRXP's expansion strategy?
